107 related articles for article (PubMed ID: 28661592)
1. [[LIVER TOXICITY DUE TO RIFAMPICIN MONOTHERAPY IN LATENT TUBERCULOSIS INFECTION].].
Ito K
Kekkaku; 2016 May; 91(5):509-513. PubMed ID: 28661592
[TBL] [Abstract][Full Text] [Related]
2. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
[TBL] [Abstract][Full Text] [Related]
3. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
4. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
5. Safety and completion of a 4-month course of rifampicin for latent tuberculous infection in children.
Cruz AT; Starke JR
Int J Tuberc Lung Dis; 2014 Sep; 18(9):1057-61. PubMed ID: 25189552
[TBL] [Abstract][Full Text] [Related]
6. [TREATMENT OF LATENT TUBERCULOSIS INFECTION WITH A COMBINATION OF ISONIAZID AND RIFAMPICIN].
Ito K
Kekkaku; 2016 Oct; 91(10):641-655. PubMed ID: 30646449
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study on the cases in which INH or RFP was discontinued during treatment for pulmonary tuberculosis].
Harada S; Takamoto M; Ishibashi T; Mohri M; Sato K; Yamagishi F; Sasaki Y; Tanabe K; Sato R; Fujino T; Tano M; Tanizawa M; Sakatani M; Morimoto T; Kawahara S; Hotta N; Shigeto E; Nishimura K; Abe T; Iwanaga T; Oe T; Shimazu K; Ebihara M; Nakagawa S; Kuba M;
Kekkaku; 2001 May; 76(5):427-36. PubMed ID: 11449698
[TBL] [Abstract][Full Text] [Related]
8. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis.
den Boon S; Matteelli A; Getahun H
Int J Tuberc Lung Dis; 2016 Aug; 20(8):1065-71. PubMed ID: 27393541
[TBL] [Abstract][Full Text] [Related]
9. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
10. Treatment of latent tuberculosis infection: An update.
Lobue P; Menzies D
Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
[TBL] [Abstract][Full Text] [Related]
11. [FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION].
Ito K
Kekkaku; 2016 Sep; 91(9):607-616. PubMed ID: 30646464
[TBL] [Abstract][Full Text] [Related]
12. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City.
Anger HA; Proops D; Harris TG; Li J; Kreiswirth BN; Shashkina E; Ahuja SD
Clin Infect Dis; 2012 May; 54(9):1287-95. PubMed ID: 22412056
[TBL] [Abstract][Full Text] [Related]
13. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
Fluegge KR
J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
[TBL] [Abstract][Full Text] [Related]
14. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection.
Haley CA; Stephan S; Vossel LF; Sherfy EA; Laserson KF; Kainer MA
Int J Tuberc Lung Dis; 2008 Feb; 12(2):160-7. PubMed ID: 18230248
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children.
Bright-Thomas R; Nandwani S; Smith J; Morris JA; Ormerod LP
Arch Dis Child; 2010 Aug; 95(8):600-2. PubMed ID: 20530147
[TBL] [Abstract][Full Text] [Related]
16. [Treatment outcome of latent tuberculosis infection in persons with fibrotic pulmonary lesions].
Komukai J; Matsumoto K; Kudoh S; Okado A; Yoshiyama T; Yoshida H; Shimouchi A
Nihon Koshu Eisei Zasshi; 2021 Jun; 68(6):405-411. PubMed ID: 33790095
[TBL] [Abstract][Full Text] [Related]
17. [Changes in blood coagulation affected by rifampicin administration].
Zhang H; Bu R; Fang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Aug; 22(8):478-80. PubMed ID: 11776563
[TBL] [Abstract][Full Text] [Related]
18. Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation.
Hickey MD; Quan DJ; Chin-Hong PV; Roberts JP
Liver Transpl; 2013 Apr; 19(4):457-61. PubMed ID: 23526600
[TBL] [Abstract][Full Text] [Related]
19. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.
Spyridis NP; Spyridis PG; Gelesme A; Sypsa V; Valianatou M; Metsou F; Gourgiotis D; Tsolia MN
Clin Infect Dis; 2007 Sep; 45(6):715-22. PubMed ID: 17712755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
